Recent earnings call highlights and transcripts from Q4 2025 through Q2 2026 provide insights into Sensus Healthcare's operational performance, strategic initiatives, and financial results.

• Sensus Healthcare held Q2 2026 earnings call highlighting operational and financial updates [N1].
• Q1 2026 earnings call and transcript provided details on company performance and strategy [N2][N3].
• Q4 2025 earnings transcript discussed year-end results and outlook [N4].
• Q3 2025 earnings call and transcript reviewed quarterly performance and challenges [N5].
• Sensus reported Q3 2025 loss but topped revenue estimates [N6].
• Stock movement and market commentary were noted in late 2025 [N7].

Sensus Healthcare’s technology addresses a significant medical need with a non-invasive treatment alternative for non-melanoma skin cancer and keloids. The company’s expanding product portfolio, including advanced imaging and software connectivity solutions, enhances clinical precision and workflow efficiency. The Fair Deal Agreement and financing programs lower barriers for customer adoption and support recurring revenue streams. The company’s strong liquidity position and credit facility provide financial flexibility. Growth opportunities exist in dermatology, radiation oncology, and adjacent markets such as plastic surgery and aesthetic dermatology. Continued regulatory compliance and intellectual property protection support competitive positioning.

Sensus Healthcare operates in a highly competitive and rapidly evolving medical device industry subject to technological change and regulatory scrutiny. The company has reported net losses and modest revenue, indicating challenges in achieving profitability. Dependence on third-party manufacturers and a single preferred supplier for key components could pose supply risks. Regulatory changes or compliance failures could impact operations. Market acceptance depends on physician and patient adoption, reimbursement policies, and competitive alternatives. The company’s limited sales and marketing scale and reliance on a multi-tier sales model may constrain growth. Financial losses and the need for ongoing investment in research and development and commercialization present risks.

Sensus Healthcare’s moat is anchored in its proprietary SRT technology, which offers a non-invasive, painless alternative to surgery for non-melanoma skin cancer and keloid scar treatment. The company’s portfolio of devices, including advanced models with integrated imaging and treatment planning, provides clinical and operational advantages. Its intellectual property portfolio, including multiple patents and trademarks, supports competitive differentiation. The Fair Deal Agreement service model and financing program enhance customer accessibility and recurring revenue potential. Regulatory clearances and compliance with quality standards further establish barriers to entry. The company’s multi-tier sales strategy and established installed base in multiple countries contribute to market presence and customer relationships.

• Regulatory Compliance Risk: Sensus is subject to extensive U.S. and international medical device regulations. Non-compliance or changes in regulatory requirements could result in fines, penalties, or restrictions affecting product marketing and sales.
• Market Acceptance Risk: The company’s success depends on acceptance of its SRT technology by dermatologists, radiation oncologists, and patients. Competition from alternative treatments and devices may limit market penetration.
• Supply Chain Risk: Reliance on third-party manufacturers and a single preferred supplier for major components could lead to supply disruptions or increased costs.
• Financial Risk: Sensus has reported net losses and depends on liquidity and credit facilities to fund operations. Continued losses or inability to secure financing could impact business continuity.
• Intellectual Property Risk: Patents and trademarks may not provide complete protection. Intellectual property could be challenged or infringed, affecting competitive advantage.

• Sensus Healthcare, Inc. is a medical device company focused on non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention using proprietary low-energy X-ray superficial radiation therapy (SRT) technology [S1].
• The company offers a portfolio of treatment devices including the SRT-100, SRT-100+, and SRT-100 Vision, with approximately 955 units installed in 21 countries as of December 31, 2025, primarily in the U.S. [S1].
• SRT technology provides an alternative to surgery for NMSC and keloids, offering advantages such as non-scarring treatment, no need for anesthetics, and suitability for sensitive areas [S1].
• Sensus Healthcare Services, LLC, a wholly owned subsidiary formed in February 2024, provides operational healthcare services including equipment, radiation oncology and physicist oversight, and on-site device operation by radiotherapy technologists under a 'Fair Deal Agreement' revenue-share model [S1].
• In February 2026, the company launched Sensus Healthcare Financial Services, a financing program through third-party banks to support acquisition of its systems via purchase or leasing, aiming to reduce administrative and financing barriers [S1].
• Also in February 2026, Sensus launched Sensus Link, a cloud-based software and connectivity solution enhancing workflow, treatment documentation, and operating intelligence for its installed base [S1].
• The company sells consumables such as disposable lead shielding, radiation safety items, ultrasound probe film, and applicator tips [S1].
• Sensus uses third-party manufacturers in the U.S., primarily RbM Services, LLC, under agreements with fixed pricing and quality standards compliance including FDA and ISO requirements. It also contracts with Koplak, LLC for special projects [S1].
• The company holds eight issued U.S. and global patents related to its technology, with patent expirations ranging from 2033 to 2039, and owns eight U.S. trademark registrations [S1].
• Sensus operates mainly in two primary markets: private dermatology practices and radiation oncologists in private and hospital settings, using a multi-tier sales strategy with direct U.S. sales and international dealers/distributors [S1].
• The company believes its SRT products allow dermatologists to retain NMSC patients and offer radiation oncologists a simpler, faster treatment method that frees up more expensive equipment [S1].
• Sensus has FDA clearance to treat keloid scars since 2014 and its SRT has been used by over 100 U.S. dermatology practices and in China since 2017 for keloids [S1].
• The company did not sell any laser devices in 2024 or 2025 but distributes lasers for aesthetic dermatology applications [S1].
• Sensus is subject to extensive U.S. and international regulations including FDA medical device regulations (Class II devices), EU Medical Device Regulation, and other country-specific requirements [S1].
• For the quarter ended June 30, 2026, Sensus reported revenue of $2.29 million, net loss of $8.749 million, and basic and diluted EPS of -$0.53 [S2].
• As of June 30, 2026, the company had cash and equivalents of $15.186 million, current assets of $37.677 million, current liabilities of $4.327 million, with a current ratio of 8.71 and cash ratio of 3.51, indicating strong liquidity [S2].
• In June 2026, Sensus entered into a revolving credit facility with City National Bank of Florida for up to $15 million, secured by cash collateral and company assets [S19].
• Recent earnings call highlights and transcripts from Q4 2025 through Q2 2026 provide insights into operational performance and strategic initiatives [N1][N2][N3][N4][N5][N6].